Clin2
NCT07705919Possibly a fitNot yet recruiting

MRI scan to guide treatment for pancreatic cancer

Borderline Resectable Pancreatic Ductal Adenocarcinoma

Treatments studied

Part of Cancer, Digestive system clinical trials.

This trial tests whether a special MRI scan can help doctors better plan treatment for people with pancreatic cancer that is borderline able to be removed by surgery. The study will check how the tumor responds to initial treatment before surgery.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
50 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must be 18 years or older.
  • You must have been diagnosed with pancreatic cancer that is borderline resectable (can potentially be removed with surgery after treatment).
  • You must not have received any prior treatment for pancreatic cancer, including surgery, chemotherapy, radiation, or other cancer therapies.
  • You must have adequate blood counts and liver function as determined by blood tests within the past month.
  • If you are able to become pregnant, you must have a negative pregnancy test and agree to use effective birth control during and for 6 months after the study. If you are a male partner, you must agree to use effective birth control for 3 months after the study.
  • You must be willing and able to follow all study procedures and attend all study visits.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07748611Not yet recruiting· Phase 2
Chemotherapy matched to tumor gene type for pancreatic cancer

This study tailors standard chemotherapy for pancreatic cancer based on whether the tumor has a change in the SMAD4 gene. The goal is to see if a specific treatment plan works better for each gene type.

Chicago, Illinois
NCT06821997Recruiting· Phase 2
Chemotherapy Before Surgery for Borderline Resectable Pancreatic Cancer

This trial is testing a combination of three chemotherapy drugs (NALIRIFOX) given before surgery to shrink borderline resectable pancreatic cancer. The goal is to help make surgery more successful and improve outcomes.

Buffalo, New York
NCT04588025Recruiting
MRI study using a special model to measure pancreatic cancer response

This study tests a new, harmless “disposable” setup for MRI scans to measure how pancreatic cancer treatments affect the body. It may help doctors get more accurate MRI measurements, so treatment response can be assessed better.

Columbus, Ohio
NCT06600906Recruiting
MRI test to predict treatment response in pancreatic cancer

This study is testing a new MRI technique that may help predict how well pancreatic cancer treatments will work. You would receive a special substance (called hyperpolarized pyruvate) during a standard MRI scan.

San Francisco, California
NCT05428358Recruiting
MRI helps choose which pancreatic cancer patients can have surgery

This trial studies whether adding an MRI scan improves the selection of people with pancreatic cancer who may benefit from surgery. It focuses on patients without liver spread and with tumors that are borderline or likely removable.

Aalborg
NCT07080021Recruiting
Tracking ctDNA for Pancreatic Cancer Before Surgery

This study looks at using a special blood test (ctDNA MRD) to track how well the tumor responds to chemotherapy before surgery for pancreatic cancer. It may help doctors decide if the treatment is working and guide next steps.

Shanghai

Hear when a new Borderline Resectable Pancreatic Ductal Adenocarcinoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.